Caris Life Sciences Coasts Past A Buy Point; Why This Texas Biotech Researcher Deserves A Look
Caris Life Sciences Inc CAI
$31.98
▼ -0.90%
($-0.29)
Open
$32.65
Prev Close
$32.27
Day Range
$31.59 – $32.77
52W Range
$14.19 – $33.66
Market Cap
$9.04B
P/E (TTM)
86.74
Beta
0.40
EPS (TTM)
$0.37
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2025-06-18 |
| Shares Out. | 282,680,000 |
| Website | carislifesciences.com/ ↗ |
| Phone | 18667718946 |
| Employees | 1,846 |
| Revenue | $263.7M |
| Gross Profit | $179.6M |
| Net Income | -$637,000 |
| Free Cash Flow | $124.0M |
| Total Assets | $1.23B |
| Total Liabilities | $637.9M |
| Equity | $591.7M |
About Caris Life Sciences Inc
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
Caris Life Sciences Inc is a publicly traded company under the ticker symbol CAI on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
16 analysts (2026-09-01)
📰 Latest News for CAI
Caris Life Sciences: Adjusting My Position After A Recent Steep Incline (Downgrade)
Are Medical Stocks Lagging Bristol Myers Squibb (BMY) This Year?
Caris Life Sciences Stock Jumped 10% Yesterday. Here’s Where Shares Could Go Further in 2026.
Caris Life Sciences: Diagnostics Growth With Room To Run
Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division
Strength Seen in Revvity (RVTY): Can Its 9.1% Jump Turn into More Strength?
Caris Life Sciences, Inc. (CAI) Soars 9.4%: Is Further Upside Left in the Stock?